Theriva Biologics Inc. Secures $7.5 Million in Public Offering

ROCKVILLE, Md., May 8, 2025 — Theriva Biologics Inc. (NYSE American: TOVX), a clinical-stage biotechnology company focused on developing innovative cancer therapies, announced the successful closing of a $7.5 million public offering. This funding is aimed at advancing the company’s pipeline of therapeutics designed to address high unmet needs in cancer treatment.

The public offering was priced on May 7, 2025, as reported by multiple financial news sources, including Seeking Alpha and Finviz. Despite the successful pricing, Theriva Biologics’ shares experienced a decline following the announcement, as noted by Investing.com. However, retail investor sentiment remains strong, indicating continued interest in the company’s potential.

Clinical Trial Success

In addition to the financial developments, Theriva Biologics achieved significant milestones in its VIRAGE Phase 2b clinical trial. The trial evaluated the efficacy and safety of VCN-01 in combination with gemcitabine/nab-paclitaxel in newly-diagnosed metastatic pancreatic cancer patients. The results demonstrated that patients receiving the combination therapy experienced increased overall survival, progression-free survival, and duration of response compared to those receiving standard chemotherapy alone.

These promising outcomes highlight the potential of Theriva Biologics’ adenovirus platform in enhancing the effectiveness of existing cancer treatments and stimulating a robust anti-tumor immune response.

Company Overview

Theriva Biologics, headquartered in Rockville, United States, operates within the health care sector, specifically in biotechnology. The company specializes in developing an adenovirus platform for intravenous, intravitreal, and antitumoral delivery. This platform is designed to induce tumor cell death, improve the delivery of co-administered cancer therapies, and promote a sustained anti-tumor response.

As of May 4, 2025, Theriva Biologics’ stock closed at $1.40, with a 52-week high of $10.75 and a low of $0.96. The company’s market capitalization stands at $3.9 million, and it has a negative price-to-earnings ratio of -0.004931, reflecting its current financial performance and growth potential.

For more information, visit Theriva Biologics’ website .